{"entity":{"id":"nct05335993","kind":"trial","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","aka":[],"tldr":"A phase 2 trial of Oregovomab, Niraparib in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.","summary":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT05335993 by CanariaBio Inc., with 10 participants enrolled, started 2022-07-25 and due to reach its primary completion in 2026-12-30. Interventions recorded: Oregovomab, Niraparib. Conditions listed: Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05335993","url":"https://clinicaltrials.gov/study/NCT05335993"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-sensitive-ovarian-cancer"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["oregovomab","niraparib"],"companies":["canariabio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05335993","phase":"2","setting":"Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer","sponsor":"CanariaBio Inc.","started":"2022-07-25","startedType":"actual","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05335993/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/"}],"company":[{"id":"canariabio","kind":"company","name":"CanariaBio","route":"/companies/canariabio/"}]}}